Last reviewed · How we verify
Ginger Oil
Ginger Oil, marketed by Ain Shams University, is a natural product currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that could help maintain market position. The primary risk is the lack of clear primary indication and revenue data, which may limit its commercial potential and competitive positioning.
At a glance
| Generic name | Ginger Oil |
|---|---|
| Also known as | Ginger, Zingiber officinale, Zingiber genus |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metabolic and Epigenetic Impact of FAAH Inhibitors and OEA (NA)
- Aromatherapy in Reducing PONV for Total Joint Replacement Patients (NA)
- Role of Race in Nutritional Approach in Men on ADT (NA)
- Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting (NA)
- Culinary Spices in Metabolic Syndrome. (NA)
- Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies (NA)
- Effects of Acupressure and Aromatherapy on Nausea and Vomiting Severity, Anxiety and Comfort Level (NA)
- A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ginger Oil CI brief — competitive landscape report
- Ginger Oil updates RSS · CI watch RSS
- Ain Shams University portfolio CI